NCT07855055Not yet recruiting
Early Changes in Inflammatory Indices and Healing in IBD
Early Kinetic Changes in Blood-Based Inflammatory Indices as Predictors of Endoscopic and Histological Healing in Patients With Inflammatory Bowel Disease
Source: ClinicalTrials.gov · Last updated 2 Oct 2026
Brief summary (registry, in English)
This prospective observational study aims to evaluate early changes in blood-based inflammatory indices during the first 4 weeks after treatment initiation or escalation and their relation to endoscopic and histological healing at 12 to 16 weeks in adult patients with inflammatory bowel disease.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 138 (estimated)
- First submitted
- 27 Sept 2026
- Start date
- 30 Sept 2026
- Primary completion date
- 30 Sept 2027
- Lead sponsor
- Assiut University
- Diseases
- Crohn's disease, Ulcerative colitis
- NCT number
- NCT07855055
What you commit to
- Study type: Observational
- Planned participants: 138
- From 30 Sept 2026 to the primary completion date, 30 Sept 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Recent major surgery
- Concomitant autoimmune inflammatory disease
- Systemic corticosteroids used for another indication
Other illness
- Active infection
- Malignancy
- Significant uncontrolled liver disease
- Severe renal disease expected to substantially affect inflammatory markers
- Acute severe infection around the time of blood sampling
Lab values
- Hematological malignancy or disorder substantially altering leukocyte or platelet counts
Other
- Recent blood transfusion
- Pregnancy
- Inadequate follow-up or missing essential data
Who the study is looking for
- Age 18 years or older
- Confirmed diagnosis of ulcerative colitis or Crohn's disease
- Objective evidence of active disease at baseline
- Planned initiation or escalation of IBD treatment
- Baseline CBC with differential, CRP, and serum albumin available
- Planned follow-up assessment at approximately 12-16 weeks
- Planned follow-up colonoscopy with mucosal biopsies at approximately 12-16 weeks
- Written informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.